[The renin-angiotensin system and its inhibition (author's transl)].
The recent development of several inhibitors of the renin-angiotensin system has perfected our knowledge of the part played by this system in the control of physiological and pathological arterial pressure. Peptides inhibiting angiotensin II, such as Sar1, Ala8 angiotensin II, block the peripheral effects of angiotensin on vascular renal and adrenal receptors. Inhibition of the conversion enzyme, notably with captopril, prevents the formation of angiotensin II from angiotensin I and also results in accumulation of a vasodilator and natriuretic peptide: bradykinin. Finally, it is now possible to inhibit more specifically the reaction of renin with its substrate, angiotensinogen, by using pepstatin or its derivatives, or peptide analogues of the substrate. The use of these inhibitors, especially captopril (so far the most studied), has made it clear that renin plays a part in experimental and human essential hypertension and participates in the control of arterial blood pressure in subjects with normal sodium intake.
D000806:Angiotensin-Converting Enzyme Inhibitors; D000808:Angiotensinogen / Q000037:antagonists & inhibitors; D000809:Angiotensins / Q000037:antagonists & inhibitors / Q000502:physiology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D051381:Rats; D012083:Renin / Q000502:physiology*; D000092502:Renin Inhibitors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000808:Angiotensinogen; D000809:Angiotensins; D002216:Captopril; D012083:Renin; D000092502:Renin Inhibitors
Le système rénine angiotensine et son inhibition.